



PRESS RELEASE

Ocumetics engages intraocular lens product and marketing expert

Dean Burns, a 27-year Alcon veteran, rounds out the Ocumetics leadership team

For Immediate Release

Calgary, Alberta – February 15, 2022. Ocumetics Technology Corp. (“**Ocumetics**”) (TSXV:“OTC”) is pleased to announce that Mr. Dean Burns of Atlanta, Georgia has joined Ocumetics as an intraocular lens product and marketing consultant.

Mr. Burns will help guide Ocumetics, from a product and marketing perspective, as Ocumetics proceeds from preclinical studies through commercialization of its Bionic Lens™ technology.

Dean Burns recently retired from Alcon Vision, where he was the Senior Director of Cataract instrumentation and advanced consumable technology, a \$750 million division of Alcon. At Alcon, Dean managed technologies in four therapeutic categories: Cataract, Refractive, Retinal and Pharmaceutical. Dean’s 27-year career with Alcon brings a diverse healthcare experience to Ocumetics. His experience included developing plans to commercialize acquired technologies and line extension of existing products. He also has skills and experience in marketing and sales management, comprehensive understanding of the regulatory process for devices, Key Opinion Leader management, and surgeon clinical training. Dean’s accomplishments during his tenure include over 15 FDA product approvals, and 5 business development and licensing acquisition projects totaling US\$2.3 billion.

“We are most fortunate to have Dean Burns join our team,” said Dr. Mark Lee, President & CEO of Ocumetics. “Dean brings a wealth of experience navigating intraocular lens products through preclinical studies, clinical trials, product launches and full global commercialization.”

“Dean has worked previously with Dr. Doyle Stulting, our Chief Medical Officer, and Dr. Barbara Fant, whom we have recently engaged to lead our regulatory strategy,” adds Dr. Lee. “We are confident this talented team will assist our Founder, Dr. Garth Webb, expedite the process of bringing the Bionic Lens™ technology to the marketplace.”

“I’m honoured to work with Dr. Stulting and Dr. Fant again,” said Dean Burns. “They are the best in their fields, and I’m ready to help them and the Ocumetics team navigate the Bionic Lens™ through preclinical studies, clinical trials and global product launches.”

About Ocumetics

Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry - the Bionic Lens™. The Bionic Lens™ is an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee
President and CEO
(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.